Literature DB >> 22407287

Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Peng Zou1, Yanke Yu, Nan Zheng, Yongsheng Yang, Hayley J Paholak, Lawrence X Yu, Duxin Sun.   

Abstract

Quantitative estimations of first-in-human (FIH) doses are critical for phase I clinical trials in drug development. Human pharmacokinetic (PK) prediction methods have been developed to project the human clearance (CL) and bioavailability with reasonable accuracy, which facilitates estimation of a safe yet efficacious FIH dose. However, the FIH dose estimation is still very challenging and complex. The aim of this article is to review the common approaches for FIH dose estimation with an emphasis on PK-guided estimation. We discuss 5 methods for FIH dose estimation, 17 approaches for the prediction of human CL, 6 methods for the prediction of bioavailability, and 3 tools for the prediction of PK profiles. This review may serve as a practical protocol for PK- or pharmacokinetic/pharmacodynamic-guided estimation of the FIH dose.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407287      PMCID: PMC3326168          DOI: 10.1208/s12248-012-9332-y

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  98 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

3.  Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans.

Authors:  I Mahmood
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

4.  A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods.

Authors:  I Mahmood; R Yuan
Journal:  Biopharm Drug Dispos       Date:  1999-04       Impact factor: 1.627

5.  QSAR model for drug human oral bioavailability.

Authors:  F Yoshida; J G Topliss
Journal:  J Med Chem       Date:  2000-06-29       Impact factor: 7.446

Review 6.  Prediction of hepatic metabolic clearance: comparison and assessment of prediction models.

Authors:  J Zuegge; G Schneider; P Coassolo; T Lavé
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

8.  First time in human for GV196771: interspecies scaling applied on dose selection.

Authors:  L Iavarone; J F Hoke; M Bottacini; R Barnaby; G C Preston
Journal:  J Clin Pharmacol       Date:  1999-06       Impact factor: 3.126

9.  Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship.

Authors:  C W Andrews; L Bennett; L X Yu
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

10.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.

Authors:  G Schneider; P Coassolo; T Lavé
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

View more
  22 in total

1.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

Review 2.  Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.

Authors:  Christopher R Jones; Oliver J D Hatley; Anna-Lena Ungell; Constanze Hilgendorf; Sheila Annie Peters; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-03-10       Impact factor: 4.009

3.  Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.

Authors:  Teerachat Saeheng; Kesara Na-Bangchang; Juntra Karbwang
Journal:  Eur J Clin Pharmacol       Date:  2018-07-05       Impact factor: 2.953

4.  Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.

Authors:  Chang Ren; Yao Wang; Mei Zhang; Dexuan Kong; Chen Ning; Yujie Cheng; Yueying Bian; Mengqi Sun; Shengdi Su; Yucong Wang; Yongjie Zhang; Yang Lu; Ning Li; Di Zhao; Xijing Chen
Journal:  Pharm Res       Date:  2021-11-12       Impact factor: 4.200

5.  Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.

Authors:  Kristyn Pantoja; Shankar Lanke; Alain Munafo; Anja Victor; Christina Habermehl; Armin Schueler; Karthik Venkatakrishnan; Pascal Girard; Kosalaram Goteti
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-08-05

6.  Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity.

Authors:  Ling Zou; Adrian Stecula; Anshul Gupta; Bhagwat Prasad; Huan-Chieh Chien; Sook Wah Yee; Li Wang; Jashvant D Unadkat; Simone H Stahl; Katherine S Fenner; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2018-05-02       Impact factor: 4.436

Review 7.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

8.  Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.

Authors:  Hong Li; Kathleen Köck; John A Wisler; William A Rees; Peter J Prince; Kai O Reynhardt; Hailing Hsu; Zhigang Yu; Dominic C Borie; David H Salinger; Wei-Jian Pan
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

9.  A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning-integrated modeling platform.

Authors:  Victor Antontsev; Aditya Jagarapu; Yogesh Bundey; Hypatia Hou; Maksim Khotimchenko; Jason Walsh; Jyotika Varshney
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.

Authors:  M Sundqvist; A Lundahl; M B Någård; U Bredberg; P Gennemark
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.